25 XP   0   0   10

Enzon Pharmaceuticals Inc
Buy, Hold or Sell?

Let's analyse Enzon together

PenkeI guess you are interested in Enzon Pharmaceuticals Inc. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

I'm going to help you getting a better view of Enzon Pharmaceuticals Inc. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

You can find me behind Let's Analyse Together in the top-right of each section.

Get notifications about Enzon Pharmaceuticals Inc

I send you an email if I find something interesting about Enzon Pharmaceuticals Inc.

Quick analysis of Enzon (30 sec.)










What can you expect buying and holding a share of Enzon? (30 sec.)

How much money do you get?

How much money do you get?
$0.02
When do you have the money?
1 year
How often do you get paid?
40.0%

What is your share worth?

Current worth
$0.05
Expected worth in 1 year
$-0.52
How sure are you?
57.5%

+ What do you gain per year?

Total Gains per Share
$-0.55
Return On Investment
-710.2%

For what price can you sell your share?

Current Price per Share
$0.08
Expected price per share
$0.06 - $0.09
How sure are you?
50%

1. Valuation of Enzon (5 min.)




Live pricePrice per Share (EOD)

$0.08

Intrinsic Value Per Share

$-0.64 - $0.78

Total Value Per Share

$-0.60 - $0.82

2. Growth of Enzon (5 min.)




Is Enzon growing?

Current yearPrevious yearGrowGrow %
How rich?$3.5m$35.9m-$22m-159.4%

How much money is Enzon making?

Current yearPrevious yearGrowGrow %
Making money$343.2k-$46.5k$389.7k113.5%
Net Profit Margin0.0%320.2%--

How much money comes from the company's main activities?

3. Financial Health of Enzon (5 min.)




4. Comparing to competitors in the Biotechnology industry (5 min.)




  Industry Rankings (Biotechnology)  


Richest
#781 / 1010

Most Revenue
#968 / 1010

Most Profit
#153 / 1010

Most Efficient
#391 / 1010

What can you expect buying and holding a share of Enzon? (5 min.)

Welcome investor! Enzon's management wants to use your money to grow the business. In return you get a share of Enzon.

What can you expect buying and holding a share of Enzon?

First you should know what it really means to hold a share of Enzon. And how you can make/lose money.

Speculation

The Price per Share of Enzon is $0.078. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Enzon.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Enzon, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is $0.05. Based on the TTM, the Book Value Change Per Share is $-0.14 per quarter. Based on the YOY, the Book Value Change Per Share is $0.14 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is $0.00 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Enzon.

How much money are you going to get?

 MRQTTMYOY5Y10Y
 $% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share
Usd Eps0.0111.6%0.001.3%0.00-6.3%0.00-5.5%0.0223.4%
Usd Book Value Change Per Share0.0117.1%-0.14-183.0%0.14177.2%-0.01-9.9%0.00-0.8%
Usd Dividend Per Share0.000.0%0.005.5%0.000.0%0.018.0%0.0341.8%
Usd Total Gains Per Share0.0117.1%-0.14-177.5%0.14177.2%0.00-1.9%0.0341.0%
Usd Price Per Share0.09-0.18-0.29-0.29-0.44-
Price to Earnings Ratio2.48--3.34--4.22--21.10--9.76-
Price-to-Total Gains Ratio6.75-1.59--357.90-14.40-12.45-
Price to Book Ratio1.91-3.23-1.71-2.42-2.50-
Price-to-Total Gains Ratio6.75-1.59--357.90-14.40-12.45-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share0.078
Number of shares12820
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.000.01
Usd Book Value Change Per Share-0.14-0.01
Usd Total Gains Per Share-0.140.00
Gains per Quarter (12820 shares)-1,775.36-19.47
Gains per Year (12820 shares)-7,101.44-77.87
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
1220-7322-7111319-397-88
2440-14643-14212638-794-166
3661-21965-21313957-1191-244
4881-29287-284141276-1588-322
51101-36608-355151595-1984-400
61321-43930-426161914-2381-478
71542-51252-497172233-2778-556
81762-58573-568182552-3175-634
91982-65895-639192871-3572-712
102202-73217-710203190-3969-790

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share2.02.00.050.0%3.09.00.025.0%3.017.00.015.0%18.022.00.045.0%46.026.021.049.5%
Book Value Change Per Share2.02.00.050.0%4.08.00.033.3%5.015.00.025.0%18.022.00.045.0%48.045.00.051.6%
Dividend per Share1.00.03.025.0%1.00.011.08.3%3.00.017.015.0%16.00.024.040.0%23.00.070.024.7%
Total Gains per Share2.02.00.050.0%4.08.00.033.3%6.014.00.030.0%23.017.00.057.5%56.037.00.060.2%

Fundamentals of Enzon

About Enzon Pharmaceuticals Inc

Enzon Pharmaceuticals, Inc., together with its subsidiaries, does not have significant operations. Previously, the company marketed its patented drug product, PegIntron. It also had a marketing agreement with Micromet AG relating to the Vicineum drug; and a licensing agreement regarding SC Oncaspar and certain other drugs. The company was formerly known as Enzon, Inc and changed its name to Enzon Pharmaceuticals, Inc. in December 2002. Enzon Pharmaceuticals, Inc. was incorporated in 1981 and is headquartered in Cranford, New Jersey.

Fundamental data was last updated by Penke on 2024-04-21 09:47:04.

Financial Health

Profitability Details
 Compared to previous yearCompared to industry
Using its assets, the company is inefficient in making profit.
Using its investors money, the company is less efficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
Liquidity Details
 Compared to previous yearCompared to industry
The company is very able to pay all its short-term debts.
Solvency Details
 Compared to previous yearCompared to industry
The company is able to pay all its debts by selling its assets.
The company is unable to pay all its debts with equity.

Valuation

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is fair priced.
Based on the earnings, the company is expensive.
Based on how much money comes from the company's main activities, the company is cheap.

1.1. Profitability of Enzon Pharmaceuticals Inc.

1.1. Profitability
1.1.1. Net Profit Margin

Measures how much net profit Enzon earns for each $1 of revenue.

  • Above 10% is considered healthy but always compare Enzon to the Biotechnology industry mean.
  • A Net Profit Margin of 0.0% means that $0.00 for each $1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Enzon Pharmaceuticals Inc:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.0%
TTM-YOY320.2%-320.2%
TTM-5Y-1,849.6%+1,849.6%
5Y-1,849.6%10Y-871.0%-978.5%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ--200.1%+200.1%
TTM--216.8%+216.8%
YOY320.2%-288.3%+608.5%
5Y-1,849.6%-449.1%-1,400.5%
10Y-871.0%-605.5%-265.5%
1.1.2. Return on Assets

Shows how efficient Enzon is using its assets to generate profit.

  • Above 5% is considered healthy but always compare Enzon to the Biotechnology industry mean.
  • 1.4% Return on Assets means that Enzon generated $0.01 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Enzon Pharmaceuticals Inc:

  • The MRQ is 1.4%. Using its assets, the company is less efficient in making profit.
  • The TTM is 0.7%. Using its assets, the company is inefficient in making profit. -1
Trends
Current periodCompared to+/- 
MRQ1.4%TTM0.7%+0.7%
TTM0.7%YOY-0.1%+0.8%
TTM0.7%5Y-1.2%+1.9%
5Y-1.2%10Y5.7%-6.9%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ1.4%-13.3%+14.7%
TTM0.7%-12.8%+13.5%
YOY-0.1%-11.7%+11.6%
5Y-1.2%-13.9%+12.7%
10Y5.7%-15.7%+21.4%
1.1.3. Return on Equity

Shows how efficient Enzon is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare Enzon to the Biotechnology industry mean.
  • 19.2% Return on Equity means Enzon generated $0.19 for each $1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Enzon Pharmaceuticals Inc:

  • The MRQ is 19.2%. Using its investors money, the company is efficient in making profit. +1
  • The TTM is 9.7%. Using its investors money, the company is less efficient in making profit.
Trends
Current periodCompared to+/- 
MRQ19.2%TTM9.7%+9.5%
TTM9.7%YOY-1.7%+11.4%
TTM9.7%5Y-0.3%+10.0%
5Y-0.3%10Y7.0%-7.3%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ19.2%-16.9%+36.1%
TTM9.7%-16.1%+25.8%
YOY-1.7%-15.1%+13.4%
5Y-0.3%-19.3%+19.0%
10Y7.0%-20.2%+27.2%

1.2. Operating Efficiency of Enzon Pharmaceuticals Inc.

1.2. Operating Efficiency
1.2.1. Operating Margin

Measures how efficient Enzon is operating .

  • Measures how much profit Enzon makes for each $1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare Enzon to the Biotechnology industry mean.
  • An Operating Margin of 0.0% means the company generated $0.00  for each $1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Enzon Pharmaceuticals Inc:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.0%
TTM-YOY-202.9%+202.9%
TTM-5Y-1,947.5%+1,947.5%
5Y-1,947.5%10Y-1,067.7%-879.8%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ--296.2%+296.2%
TTM--232.5%+232.5%
YOY-202.9%-298.2%+95.3%
5Y-1,947.5%-492.1%-1,455.4%
10Y-1,067.7%-632.4%-435.3%
1.2.2. Operating Ratio

Measures how efficient Enzon is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Biotechnology industry mean).
  • An Operation Ratio of 0.00 means that the operating costs are $0.00 for each $1 in net sales.

Let's take a look of the Operating Ratio trends of Enzon Pharmaceuticals Inc:

  • The MRQ is 0.000. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.000
TTM-YOY2.279-2.279
TTM-5Y20.077-20.077
5Y20.07710Y12.937+7.140
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-3.231-3.231
TTM-3.310-3.310
YOY2.2793.890-1.611
5Y20.0775.739+14.338
10Y12.9377.876+5.061

1.3. Liquidity of Enzon Pharmaceuticals Inc.

1.3. Liquidity
1.3.1. Current Ratio

Measures if Enzon is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Biotechnology industry mean).
  • A Current Ratio of 27.62 means the company has $27.62 in assets for each $1 in short-term debts.

Let's take a look of the Current Ratio trends of Enzon Pharmaceuticals Inc:

  • The MRQ is 27.621. The company is very able to pay all its short-term debts. +2
  • The TTM is 93.028. The company is very able to pay all its short-term debts. +2
Trends
Current periodCompared to+/- 
MRQ27.621TTM93.028-65.407
TTM93.028YOY95.032-2.003
TTM93.0285Y71.483+21.546
5Y71.48310Y48.936+22.546
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ27.6213.890+23.731
TTM93.0284.173+88.855
YOY95.0325.344+89.688
5Y71.4836.126+65.357
10Y48.9366.448+42.488
1.3.2. Quick Ratio

Measures if Enzon is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare Enzon to the Biotechnology industry mean.
  • A Quick Ratio of 0.00 means the company can pay off $0.00 for each $1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Enzon Pharmaceuticals Inc:

  • The MRQ is 0.000. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.000
TTM-YOY-0.000
TTM-5Y20.114-20.114
5Y20.11410Y27.146-7.032
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-3.514-3.514
TTM-3.998-3.998
YOY-5.380-5.380
5Y20.1146.105+14.009
10Y27.1466.404+20.742

1.4. Solvency of Enzon Pharmaceuticals Inc.

1.3. Liquidity
1.4.1. Debt to Asset Ratio

Measures how much % of Enzon assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare Enzon to Biotechnology industry mean.
  • A Debt to Asset Ratio of 0.93 means that Enzon assets are financed with 92.7% credit (debt) and the remaining percentage (100% - 92.7%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of Enzon Pharmaceuticals Inc:

  • The MRQ is 0.927. The company is just able to pay all its debts by selling its assets.
  • The TTM is 0.704. The company is able to pay all its debts by selling its assets. +1
Trends
Current periodCompared to+/- 
MRQ0.927TTM0.704+0.223
TTM0.704YOY0.242+0.462
TTM0.7045Y0.323+0.380
5Y0.32310Y0.207+0.117
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.9270.339+0.588
TTM0.7040.336+0.368
YOY0.2420.271-0.029
5Y0.3230.366-0.043
10Y0.2070.389-0.182
1.4.2. Debt to Equity Ratio

Measures if Enzon is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare Enzon to the Biotechnology industry mean.
  • A Debt to Equity ratio of 1,261.0% means that company has $12.61 debt for each $1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Enzon Pharmaceuticals Inc:

  • The MRQ is 12.610. The company is unable to pay all its debts with equity. -1
  • The TTM is 11.109. The company is unable to pay all its debts with equity. -1
Trends
Current periodCompared to+/- 
MRQ12.610TTM11.109+1.501
TTM11.109YOY2.697+8.412
TTM11.1095Y3.648+7.461
5Y3.64810Y1.891+1.757
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ12.6100.388+12.222
TTM11.1090.402+10.707
YOY2.6970.335+2.362
5Y3.6480.426+3.222
10Y1.8910.461+1.430

2. Market Valuation of Enzon Pharmaceuticals Inc

2.1. Earnings Per Share
2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every $1 in earnings Enzon generates.

  • Above 15 is considered overpriced but always compare Enzon to the Biotechnology industry mean.
  • A PE ratio of 2.48 means the investor is paying $2.48 for every $1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Enzon Pharmaceuticals Inc:

  • The EOD is 2.154. Based on the earnings, the company is cheap. +2
  • The MRQ is 2.485. Based on the earnings, the company is cheap. +2
  • The TTM is -3.343. Based on the earnings, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD2.154MRQ2.485-0.331
MRQ2.485TTM-3.343+5.827
TTM-3.343YOY-4.223+0.880
TTM-3.3435Y-21.104+17.761
5Y-21.10410Y-9.758-11.345
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD2.154-2.264+4.418
MRQ2.485-2.629+5.114
TTM-3.343-2.680-0.663
YOY-4.223-4.145-0.078
5Y-21.104-6.257-14.847
10Y-9.758-6.254-3.504
2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Enzon Pharmaceuticals Inc:

  • The EOD is 3.181. Based on how much money comes from the company's main activities, the company is cheap. +2
  • The MRQ is 3.670. Based on how much money comes from the company's main activities, the company is cheap. +2
  • The TTM is 13.297. Based on how much money comes from the company's main activities, the company is cheap. +2
Trends
Current periodCompared to+/- 
EOD3.181MRQ3.670-0.489
MRQ3.670TTM13.297-9.627
TTM13.297YOY22.484-9.187
TTM13.2975Y171.428-158.131
5Y171.42810Y84.691+86.737
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD3.181-2.973+6.154
MRQ3.670-3.333+7.003
TTM13.297-3.553+16.850
YOY22.484-5.605+28.089
5Y171.428-8.376+179.804
10Y84.691-8.865+93.556
2. Book Value per Share
2.3. Price to Book Ratio

Measures if the stock price of Enzon is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy (always compare to Biotechnology industry mean).
  • A PB ratio of 1.91 means the investor is paying $1.91 for each $1 in book value.

Let's take a look of the Price to Book Ratio trends of Enzon Pharmaceuticals Inc:

  • The EOD is 1.652. Based on the equity, the company is underpriced. +1
  • The MRQ is 1.906. Based on the equity, the company is underpriced. +1
  • The TTM is 3.233. Based on the equity, the company is fair priced.
Trends
Current periodCompared to+/- 
EOD1.652MRQ1.906-0.254
MRQ1.906TTM3.233-1.327
TTM3.233YOY1.710+1.522
TTM3.2335Y2.424+0.809
5Y2.42410Y2.500-0.076
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD1.6521.896-0.244
MRQ1.9062.115-0.209
TTM3.2332.093+1.140
YOY1.7102.884-1.174
5Y2.4243.542-1.118
10Y2.5003.916-1.416
2. Total Gains per Share

3. Summary

3.1. Key Performance Indicators

The key performance indicators of Enzon Pharmaceuticals Inc compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share--0.013-0.143+1170%0.138-90%-0.008+158%-0.001+104%
Book Value Per Share--0.0470.186-75%0.484-90%0.273-83%0.251-81%
Current Ratio--27.62193.028-70%95.032-71%71.483-61%48.936-44%
Debt To Asset Ratio--0.9270.704+32%0.242+283%0.323+187%0.207+348%
Debt To Equity Ratio--12.61011.109+14%2.697+368%3.648+246%1.891+567%
Dividend Per Share---0.004-100%-0%0.006-100%0.033-100%
Eps--0.0090.001+805%-0.005+154%-0.004+148%0.018-50%
Free Cash Flow Per Share--0.0060.004+39%-0.002+136%0.004+36%0.021-71%
Free Cash Flow To Equity Per Share--0.0060.000+5967%-0.002+136%0.027-77%0.006-2%
Gross Profit Margin--1.0001.0000%1.0000%1.0000%1.0000%
Intrinsic Value_10Y_max--0.777--------
Intrinsic Value_10Y_min---0.643--------
Intrinsic Value_1Y_max--0.083--------
Intrinsic Value_1Y_min---0.010--------
Intrinsic Value_3Y_max--0.245--------
Intrinsic Value_3Y_min---0.078--------
Intrinsic Value_5Y_max--0.402--------
Intrinsic Value_5Y_min---0.197--------
Market Cap5788738.800-15%6679314.27012987555.525-49%21151161.855-68%21436887.852-69%32764818.539-80%
Net Profit Margin----0%3.202-100%-18.4960%-8.7100%
Operating Margin----0%-2.0290%-19.4750%-10.6770%
Operating Ratio----0%2.279-100%20.077-100%12.937-100%
Pb Ratio1.652-15%1.9063.233-41%1.710+11%2.424-21%2.500-24%
Pe Ratio2.154-15%2.485-3.343+235%-4.223+270%-21.104+949%-9.758+493%
Price Per Share0.078-15%0.0900.175-49%0.285-68%0.289-69%0.441-80%
Price To Free Cash Flow Ratio3.181-15%3.67013.297-72%22.484-84%171.428-98%84.691-96%
Price To Total Gains Ratio5.847-15%6.7471.593+324%-357.896+5405%14.396-53%12.451-46%
Quick Ratio----0%-0%20.114-100%27.146-100%
Return On Assets--0.0140.007+94%-0.001+107%-0.012+185%0.057-75%
Return On Equity--0.1920.097+98%-0.017+109%-0.003+102%0.070+175%
Total Gains Per Share--0.013-0.138+1138%0.138-90%-0.002+111%0.032-58%
Usd Book Value--3505000.00013840750.000-75%35903750.000-90%20288300.000-83%18616250.000-81%
Usd Book Value Change Per Share--0.013-0.143+1170%0.138-90%-0.008+158%-0.001+104%
Usd Book Value Per Share--0.0470.186-75%0.484-90%0.273-83%0.251-81%
Usd Dividend Per Share---0.004-100%-0%0.006-100%0.033-100%
Usd Eps--0.0090.001+805%-0.005+154%-0.004+148%0.018-50%
Usd Free Cash Flow--455000.000326250.000+39%-164750.000+136%333500.000+36%1544450.000-71%
Usd Free Cash Flow Per Share--0.0060.004+39%-0.002+136%0.004+36%0.021-71%
Usd Free Cash Flow To Equity Per Share--0.0060.000+5967%-0.002+136%0.027-77%0.006-2%
Usd Market Cap5788738.800-15%6679314.27012987555.525-49%21151161.855-68%21436887.852-69%32764818.539-80%
Usd Price Per Share0.078-15%0.0900.175-49%0.285-68%0.289-69%0.441-80%
Usd Profit--672000.000343250.000+96%-46500.000+107%-78600.000+112%1475700.000-54%
Usd Revenue----0%6500.000-100%49300.000-100%1832225.000-100%
Usd Total Gains Per Share--0.013-0.138+1138%0.138-90%-0.002+111%0.032-58%
 EOD+4 -4MRQTTM+18 -12YOY+14 -175Y+16 -1710Y+7 -26

3.2. Fundamental Score

Let's check the fundamental score of Enzon Pharmaceuticals Inc based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-152.154
Price to Book Ratio (EOD)Between0-11.652
Net Profit Margin (MRQ)Greater than00.000
Operating Margin (MRQ)Greater than00.000
Quick Ratio (MRQ)Greater than10.000
Current Ratio (MRQ)Greater than127.621
Debt to Asset Ratio (MRQ)Less than10.927
Debt to Equity Ratio (MRQ)Less than112.610
Return on Equity (MRQ)Greater than0.150.192
Return on Assets (MRQ)Greater than0.050.014
Total4/10 (40.0%)

3.3. Technical Score

Let's check the technical score of Enzon Pharmaceuticals Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5051.064
Ma 20Greater thanMa 500.077
Ma 50Greater thanMa 1000.078
Ma 100Greater thanMa 2000.088
OpenGreater thanClose0.078
Total1/5 (20.0%)



Latest Balance Sheet

Balance Sheet of 2023-12-31. Currency in USD. All numbers in thousands.

Summary
Total Assets47,702
Total Liabilities44,197
Total Stockholder Equity3,505
 As reported
Total Liabilities 44,197
Total Stockholder Equity+ 3,505
Total Assets = 47,702

Assets

Total Assets47,702
Total Current Assets47,343
Long-term Assets359
Total Current Assets
Cash And Cash Equivalents 47,012
Other Current Assets 331
Total Current Assets  (as reported)47,343
Total Current Assets  (calculated)47,343
+/-0
Long-term Assets
Long-term Assets  (as reported)359
Long-term Assets  (calculated)0
+/- 359

Liabilities & Shareholders' Equity

Total Current Liabilities1,714
Long-term Liabilities42,483
Total Stockholder Equity3,505
Total Current Liabilities
Accounts payable 331
Other Current Liabilities 16
Total Current Liabilities  (as reported)1,714
Total Current Liabilities  (calculated)347
+/- 1,367
Long-term Liabilities
Long-term Liabilities  (as reported)42,483
Long-term Liabilities  (calculated)0
+/- 42,483
Total Stockholder Equity
Total Stockholder Equity (as reported)3,505
Total Stockholder Equity (calculated)0
+/- 3,505
Other
Capital Stock742
Common Stock Shares Outstanding 74,215
Net Invested Capital 3,505
Net Working Capital 45,629



Balance Sheet

Currency in USD. All numbers in thousands.

 Trend2023-12-312023-09-302023-06-302023-03-312022-12-312022-09-302022-06-302022-03-312021-12-312021-09-302021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-312016-12-312016-09-302016-06-302016-03-312015-12-312015-09-302015-06-302015-03-312014-12-312014-09-302014-06-302014-03-312013-12-312013-09-302013-06-302013-03-312012-12-312012-09-302012-06-302012-03-312011-12-312011-09-302011-06-302011-03-312010-12-312010-09-302010-06-302010-03-312009-12-312009-09-302009-06-302009-03-312008-12-312008-09-302008-06-302008-03-312007-12-312007-09-302007-06-302007-03-312006-12-312006-09-302006-06-302006-03-312005-06-302005-03-312004-12-312004-09-302004-06-302004-03-312003-12-312003-09-302003-06-302003-03-312002-12-312002-09-302002-06-302002-03-312001-12-312001-09-302001-06-302001-03-312000-12-312000-09-302000-06-302000-03-31
> Total Assets 
136,528
130,252
135,792
135,182
143,690
549,676
557,426
572,543
578,721
610,747
620,375
633,912
623,787
728,566
728,124
738,397
738,693
722,410
719,223
722,584
716,628
650,861
356,816
516,119
384,375
403,830
368,809
355,431
423,518
420,357
357,889
364,865
353,350
349,253
331,906
331,094
337,675
332,749
533,142
535,790
515,080
488,857
444,843
386,699
354,538
343,209
336,946
317,049
304,468
199,781
202,298
16,649
22,862
7,121
15,217
21,901
29,322
35,040
37,830
41,288
21,407
22,890
19,862
20,791
21,740
11,271
11,298
15,648
9,053
9,512
9,300
9,010
8,734
15,510
12,554
12,403
12,070
6,478
6,237
6,004
5,824
48,232
48,292
48,246
47,963
47,754
47,470
47,224
47,257
47,589
46,495
46,672
46,997
47,702
47,70246,99746,67246,49547,58947,25747,22447,47047,75447,96348,24648,29248,2325,8246,0046,2376,47812,07012,40312,55415,5108,7349,0109,3009,5129,05315,64811,29811,27121,74020,79119,86222,89021,40741,28837,83035,04029,32221,90115,2177,12122,86216,649202,298199,781304,468317,049336,946343,209354,538386,699444,843488,857515,080535,790533,142332,749337,675331,094331,906349,253353,350364,865357,889420,357423,518355,431368,809403,830384,375516,119356,816650,861716,628722,584719,223722,410738,693738,397728,124728,566623,787633,912620,375610,747578,721572,543557,426549,676143,690135,182135,792130,252136,528
   > Total Current Assets 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
363,139
333,165
165,261
127,150
132,203
280,674
198,643
201,257
15,747
22,862
7,121
15,217
21,901
29,322
35,040
35,287
39,606
20,559
11,779
9,779
11,509
13,130
7,909
8,360
14,833
7,904
7,572
7,360
7,070
6,794
14,540
11,584
11,433
11,100
5,993
6,237
6,004
5,824
48,232
48,292
48,246
47,963
47,754
47,470
47,224
47,257
47,387
46,257
46,485
46,886
47,343
47,34346,88646,48546,25747,38747,25747,22447,47047,75447,96348,24648,29248,2325,8246,0046,2375,99311,10011,43311,58414,5406,7947,0707,3607,5727,90414,8338,3607,90913,13011,5099,77911,77920,55939,60635,28735,04029,32221,90115,2177,12122,86215,747201,257198,643280,674132,203127,150165,261333,165363,1390000000000000000000000000000000000000000000
       Cash And Cash Equivalents 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
22,360
24,224
103,516
113,645
77,146
79,987
78,128
79,711
74,052
46,845
48,614
50,440
365,203
399,180
408,594
397,530
369,938
317,867
304,995
104,324
46,214
59,441
140,946
77,348
121,742
11,456
21,691
6,520
14,863
21,477
28,993
34,562
34,804
38,993
20,255
11,672
9,735
11,231
12,896
7,639
8,079
11,206
4,320
7,478
7,240
6,966
6,726
6,500
3,558
3,367
10,016
5,446
5,144
5,909
5,311
48,142
48,187
48,191
47,891
47,641
47,429
46,794
46,852
46,982
45,877
46,131
46,557
47,012
47,01246,55746,13145,87746,98246,85246,79447,42947,64147,89148,19148,18748,1425,3115,9095,1445,44610,0163,3673,5586,5006,7266,9667,2407,4784,32011,2068,0797,63912,89611,2319,73511,67220,25538,99334,80434,56228,99321,47714,8636,52021,69111,456121,74277,348140,94659,44146,214104,324304,995317,867369,938397,530408,594399,180365,20350,44048,61446,84574,05279,71178,12879,98777,146113,645103,51624,22422,36000000000000000000000000000
       Short-term Investments 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
141,983
127,815
141,529
123,907
66,360
53,866
57,903
65,190
62,770
70,082
61,899
53,670
51,783
35,381
28,775
31,170
35,584
41,083
25,250
58,188
78,480
69,705
137,492
119,391
77,566
3,001
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0000000000000000000000000000000000000000003,00177,566119,391137,49269,70578,48058,18825,25041,08335,58431,17028,77535,38151,78353,67061,89970,08262,77065,19057,90353,86666,360123,907141,529127,815141,98300000000000000000000000000
       Net Receivables 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
2,543
1,682
848
11,111
10,083
9,282
8,610
3,362
2,938
4,315
4,649
0
0
0
0
970
970
970
970
485
970
0
0
31
65
0
0
28
0
0
0
0
0
0
0
0
00000000280065310097048597097097097000004,6494,3152,9383,3628,6109,28210,08311,1118481,6822,5430000000000000000000000000000000000000000000000000000000000
       Other Current Assets 
458
2,270
4,400
2,507
3,307
2,837
2,973
4,959
4,504
4,175
5,106
3,848
2,474
16,089
18,007
15,998
20,798
11,994
15,279
17,485
17,760
7,733
7,340
8,322
6,211
5,890
9,812
7,637
6,918
6,401
7,966
6,272
6,155
5,281
8,116
7,234
7,626
7,670
4,090
5,221
4,387
5,916
4,589
4,189
2,920
2,749
2,456
3,057
2,236
1,904
1,949
1,290
1,171
601
354
424
329
478
483
613
304
107
44
278
234
270
281
127
84
2,034
2,060
104
68
8,040
8,026
8,066
1,084
547
123
95
513
90
105
55
72
85
41
430
405
405
380
354
329
331
3313293543804054054304185725510590513951235471,0848,0668,0268,040681042,0602,03484127281270234278441073046134834783294243546011,1711,2901,9491,9042,2363,0572,4562,7492,9204,1894,5895,9164,3875,2214,0907,6707,6267,2348,1165,2816,1556,2727,9666,4016,9187,6379,8125,8906,2118,3227,3407,73317,76017,48515,27911,99420,79815,99818,00716,0892,4743,8485,1064,1754,5044,9592,9732,8373,3072,5074,4002,270458
   > Long-term Assets 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
23,560
21,373
177,948
209,796
184,846
23,794
1,138
1,041
902
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
1,940
1,940
0
970
970
970
485
0
0
0
0
0
0
0
0
0
0
0
202
238
187
111
359
3591111872382020000000000048597097097001,9401,94000000000000000000009021,0411,13823,794184,846209,796177,94821,37323,5600000000000000000000000000000000000000000000
       Property Plant Equipment 
1,761
1,789
1,821
1,939
2,336
3,420
4,505
6,608
8,909
10,102
10,552
26,621
27,564
32,593
33,252
33,315
34,178
34,859
34,468
34,152
33,518
33,214
35,008
36,067
37,576
39,491
44,446
48,150
44,790
45,312
45,269
45,012
45,006
44,585
43,386
42,053
40,623
39,237
25,406
23,177
22,116
21,574
20,223
19,485
18,065
16,802
15,506
14,240
13,323
1,138
1,041
902
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0000000000000000000000000000000000000000009021,0411,13813,32314,24015,50616,80218,06519,48520,22321,57422,11623,17725,40639,23740,62342,05343,38644,58545,00645,01245,26945,31244,79048,15044,44639,49137,57636,06735,00833,21433,51834,15234,46834,85934,17833,31533,25232,59327,56426,62110,55210,1028,9096,6084,5053,4202,3361,9391,8211,7891,761
       Goodwill 
0
0
0
0
0
0
0
0
0
0
0
150,841
150,782
150,985
150,985
150,985
150,985
150,985
150,985
150,985
150,985
150,985
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
000000000000000000000000000000000000000000000000000000000000000000000000150,985150,985150,985150,985150,985150,985150,985150,985150,985150,782150,84100000000000
       Long Term Investments 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
3,316
2,743
160,779
194,038
170,450
10,299
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
1,940
1,940
1,940
1,940
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0000000000000000000001,9401,9401,9401,9400000000000000000000010,299170,450194,038160,7792,7433,3160000000000000000000000000000000000000000000
       Intangible Assets 
0
0
0
0
0
0
0
0
0
0
0
381,740
367,230
362,960
358,483
354,006
349,529
345,052
340,573
336,061
331,602
327,127
67,131
65,112
63,093
78,510
75,910
73,309
70,723
68,141
65,559
66,077
63,366
60,654
57,941
55,227
52,514
49,801
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0000000000000000000000000000000000000000000000000000000049,80152,51455,22757,94160,65463,36666,07765,55968,14170,72373,30975,91078,51063,09365,11267,131327,127331,602336,061340,573345,052349,529354,006358,483362,960367,230381,74000000000000
       Long-term Assets Other 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
759
565
367
252
156
172
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
970
970
970
485
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
000000000000000048597097097000000000000000000000000001721562523675657590000000000000000000000000000000000000000000
> Total Liabilities 
14,992
9,290
11,868
7,737
8,554
410,687
413,647
418,435
414,779
420,252
414,667
445,718
427,528
436,982
433,973
441,393
435,890
433,319
428,766
433,408
429,926
447,359
418,139
564,578
428,729
460,271
424,291
412,206
389,872
383,784
317,776
324,039
315,152
307,592
281,545
281,217
284,272
279,466
164,977
164,590
164,416
157,000
153,383
151,245
152,798
146,028
139,800
125,530
124,753
122,313
122,842
2,600
3,083
1,866
1,444
1,263
1,102
5,437
1,060
22,828
4,761
4,801
256
150
163
940
322
487
371
368
468
379
623
517
585
455
5,753
423
424
427
654
412
461
434
42,355
42,886
43,424
377
425
1,699
43,422
402
44,482
44,197
44,19744,48240243,4221,69942537743,42442,88642,3554344614126544274244235,7534555855176233794683683714873229401631502564,8014,76122,8281,0605,4371,1021,2631,4441,8663,0832,600122,842122,313124,753125,530139,800146,028152,798151,245153,383157,000164,416164,590164,977279,466284,272281,217281,545307,592315,152324,039317,776383,784389,872412,206424,291460,271428,729564,578418,139447,359429,926433,408428,766433,319435,890441,393433,973436,982427,528445,718414,667420,252414,779418,435413,647410,6878,5547,73711,8689,29014,992
   > Total Current Liabilities 
13,551
8,172
10,756
6,447
7,271
9,410
12,378
17,172
13,523
19,700
14,141
45,218
27,054
36,533
25,306
31,433
30,147
31,664
27,359
32,255
29,027
37,854
21,775
164,408
28,465
59,885
27,938
27,535
111,707
105,482
39,139
45,232
36,228
36,094
27,481
26,906
29,740
24,997
26,328
25,901
25,919
18,387
14,529
12,480
14,766
15,264
12,970
124,890
124,301
122,313
122,842
2,600
2,487
1,308
932
796
680
5,056
709
22,506
4,761
4,801
256
150
163
940
322
487
371
368
468
379
623
517
585
455
5,753
423
424
427
654
412
461
434
377
403
410
377
425
1,699
408
402
406
1,714
1,7144064024081,6994253774104033774344614126544274244235,7534555855176233794683683714873229401631502564,8014,76122,5067095,0566807969321,3082,4872,600122,842122,313124,301124,89012,97015,26414,76612,48014,52918,38725,91925,90126,32824,99729,74026,90627,48136,09436,22845,23239,139105,482111,70727,53527,93859,88528,465164,40821,77537,85429,02732,25527,35931,66430,14731,43325,30636,53327,05445,21814,14119,70013,52317,17212,3789,4107,2716,44710,7568,17213,551
       Short-term Debt 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
115,849
115,849
115,849
115,849
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0000000000000000000000000000000000000000000115,849115,849115,849115,84900000000000000000000000000000000000000000000000
       Accounts payable 
2,300
2,465
2,945
2,986
3,476
4,670
3,606
3,657
4,618
4,526
4,837
14,192
8,289
12,809
8,124
7,772
8,001
8,663
9,169
8,614
10,821
9,874
4,173
5,545
9,570
24,918
11,852
9,004
7,027
9,441
5,545
7,298
6,510
4,443
7,843
5,572
6,007
4,265
4,213
5,335
3,438
4,192
1,405
12,480
14,766
15,264
12,970
9,041
8,452
6,464
6,993
2,600
2,487
1,308
932
796
680
5,056
709
22,506
209
295
256
150
163
940
322
487
371
368
468
379
623
517
585
455
5,753
423
424
427
654
412
461
434
331
331
331
331
331
331
331
331
337
331
3313373313313313313313313313314344614126544274244235,75345558551762337946836837148732294016315025629520922,5067095,0566807969321,3082,4872,6006,9936,4648,4529,04112,97015,26414,76612,4801,4054,1923,4385,3354,2134,2656,0075,5727,8434,4436,5107,2985,5459,4417,0279,00411,85224,9189,5705,5454,1739,87410,8218,6149,1698,6638,0017,7728,12412,8098,28914,1924,8374,5264,6183,6573,6064,6703,4762,9862,9452,4652,300
       Other Current Liabilities 
11,251
5,707
7,811
3,461
3,795
4,740
8,772
13,515
8,905
15,174
9,304
31,026
18,765
21,450
17,182
23,661
22,146
23,001
18,190
23,641
18,206
27,980
17,602
21,282
18,895
34,967
16,086
18,531
22,759
23,650
21,073
25,413
29,718
28,701
19,638
21,334
23,733
20,732
22,115
20,566
22,481
14,195
13,124
11,050
14,009
13,692
11,072
8,425
7,394
5,688
6,320
2,004
2,286
1,215
744
539
529
381
468
22,458
4,552
4,506
256
150
163
170
188
124
158
143
155
126
90
0
0
0
5,306
18
0
0
0
18
0
0
0
11
0
0
0
1,281
0
13
0
16
1601301,2810001100018000185,306000901261551431581241881701631502564,5064,55222,4584683815295397441,2152,2862,0046,3205,6887,3948,42511,07213,69214,00911,05013,12414,19522,48120,56622,11520,73223,73321,33419,63828,70129,71825,41321,07323,65022,75918,53116,08634,96718,89521,28217,60227,98018,20623,64118,19023,00122,14623,66117,18221,45018,76531,0269,30415,1748,90513,5158,7724,7403,7953,4617,8115,70711,251
   > Long-term Liabilities 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
138,765
138,032
130,764
126,830
640
452
0
0
0
596
558
512
467
422
0
351
322
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
40,460
40,966
41,472
41,978
42,483
43,014
0
0
42,483
43,014
43,545
44,076
42,483
42,48344,07643,54543,01442,4830043,01442,48341,97841,47240,96640,4600000000000000000000003223510422467512558596000452640126,830130,764138,032138,7650000000000000000000000000000000000000000000
       Long term Debt Total 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
134,499
134,499
129,499
125,749
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
00000000000000000000000000000000000000000000000125,749129,499134,499134,4990000000000000000000000000000000000000000000
       Warrants
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
40,460
40,966
41,472
0
0
0
0
0
0
0
0
0
0
000000000041,47240,96640,460000000000000000000000000000000000000000000000000000000000000000000000000000000000
       Long-term Liabilities Other 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
4,266
3,533
1,265
1,081
640
452
0
0
0
596
558
512
467
422
0
351
322
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
000000000000000000000000000000000032235104224675125585960004526401,0811,2653,5334,2660000000000000000000000000000000000000000000
> Total Stockholder Equity
121,536
120,962
123,924
127,445
135,136
138,989
143,779
154,108
163,942
190,495
205,708
188,194
196,259
291,584
294,151
297,004
302,803
289,091
290,457
289,176
286,702
203,502
0
0
0
0
0
0
33,646
36,573
40,113
40,826
38,198
41,661
50,361
49,877
53,403
53,283
368,165
371,200
350,664
331,857
291,460
235,454
201,740
197,181
197,146
191,519
179,715
77,468
79,456
14,049
19,779
5,255
13,773
20,638
28,220
29,603
36,770
18,460
16,646
18,089
19,606
20,641
21,577
10,331
10,976
15,161
8,682
9,144
8,832
8,631
8,111
14,993
11,969
11,948
6,317
6,055
5,813
5,577
5,170
47,820
47,831
47,812
5,608
4,868
4,046
46,847
46,832
45,890
3,073
46,270
2,515
3,505
3,5052,51546,2703,07345,89046,83246,8474,0464,8685,60847,81247,83147,8205,1705,5775,8136,0556,31711,94811,96914,9938,1118,6318,8329,1448,68215,16110,97610,33121,57720,64119,60618,08916,64618,46036,77029,60328,22020,63813,7735,25519,77914,04979,45677,468179,715191,519197,146197,181201,740235,454291,460331,857350,664371,200368,16553,28353,40349,87750,36141,66138,19840,82640,11336,57333,646000000203,502286,702289,176290,457289,091302,803297,004294,151291,584196,259188,194205,708190,495163,942154,108143,779138,989135,136127,445123,924120,962121,536
   Common Stock
406
408
414
417
419
420
422
430
430
430
430
434
435
435
437
438
438
438
438
439
439
442
437
438
439
440
441
441
441
442
447
448
449
450
451
454
454
453
587
607
597
588
551
506
483
483
483
475
452
437
437
437
441
441
441
441
441
441
441
441
441
441
441
439
441
441
441
441
441
442
442
442
442
442
442
442
442
442
442
442
442
742
742
742
742
742
742
742
742
742
0
742
0
0
007420742742742742742742742742742442442442442442442442442442442442442441441441441441439441441441441441441441441441441441437437437452475483483483506551588597607587453454454451450449448447442441441441440439438437442439439438438438438437435435434430430430430422420419417414408406
   Retained Earnings Total Equity0000000000-71,396-71,377-71,388-70,962-70,555-70,319-70,077-69,815-69,490-69,469-69,098-75,980-75,460-75,259-74,947-75,409-75,562-79,747-80,392-75,778-76,714-77,749-79,266-91,763-89,949-93,730-100,903-106,703-114,293-121,174-129,698-135,177-140,739-145,456-147,848-142,690-146,865-146,136-145,065-140,044-130,9390000000000000000000000000000000000000000000
   Accumulated Other Comprehensive Income 0000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000
   Capital Surplus 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
365,331
341,207
341,760
342,224
337,407
321,840
224,796
224,436
154,354
154,515
134,512
134,506
134,490
134,482
130,065
130,059
107,968
107,968
96,914
96,914
96,916
96,914
90,282
90,282
90,282
83,650
83,649
83,649
83,649
83,649
83,649
80,996
80,996
75,690
75,690
75,690
75,690
75,690
78,006
77,500
76,994
0
0
0
0
0
0
0
0
0
0
000000000076,99477,50078,00675,69075,69075,69075,69075,69080,99680,99683,64983,64983,64983,64983,64983,65090,28290,28290,28296,91496,91696,91496,914107,968107,968130,059130,065134,482134,490134,506134,512154,515154,354224,436224,796321,840337,407342,224341,760341,207365,3310000000000000000000000000000000000000000000
   Treasury Stock0000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000
   Other Stockholders Equity 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
556
94
3
575
502
113
83
39
-3
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
000000000000000000000000000000000000000000-339831135025753945560000000000000000000000000000000000000000000



Balance Sheet

Currency in USD. All numbers in thousands.




Cash Flow

Currency in USD. All numbers in thousands.




Income Statement

Currency in USD. All numbers in thousands.


Latest Income Statement (annual, 2023-12-31)

Gross Profit (+$)
totalRevenue0
Cost of Revenue-0
Gross Profit00
 
Operating Income (+$)
Gross Profit0
Operating Expense-1,044
Operating Income-1,044-1,044
 
Operating Expense (+$)
Research Development0
Selling General Administrative1,044
Selling And Marketing Expenses0
Operating Expense1,0441,044
 
Net Interest Income (+$)
Interest Income2,261
Interest Expense-0
Other Finance Cost-0
Net Interest Income2,261
 
Pretax Income (+$)
Operating Income-1,044
Net Interest Income2,261
Other Non-Operating Income Expenses0
Income Before Tax (EBT)1,217-1,044
EBIT - interestExpense = 0
1,373
1,373
Interest Expense0
Earnings Before Interest and Taxes (EBIT)01,217
Earnings Before Interest and Taxes (EBITDA)0
 
After tax Income (+$)
Income Before Tax1,217
Tax Provision--156
Net Income From Continuing Ops1,3731,373
Net Income1,373
Net Income Applicable To Common Shares0
 
Non-recurring Events
Discontinued Operations0
Extraordinary Items0
Effect of Accounting Charges0
Other Items0
Non Recurring0
Other Operating Expenses0
Total Other Income/Expenses Net0-2,261
 

Technical Analysis of Enzon
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of Enzon. The general trend of Enzon is BEARISH with 71.4% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine Enzon's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator zone transitionsBullish trend (-71.4%) Bearish trend (71.4%)
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

Support is a price level at which demand for an asset is strong enough to prevent the price from falling further.
Resistance is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of Enzon Pharmaceuticals Inc.

The long score for the Support & Resistance is 0/1.
The longshort score for the Support & Resistance is 0/(-1 +1).

  • Between support/resistance: The price is trading between support and resistance lines.

The bullish price targets are: 0.09 < 0.09 < 0.09.

The bearish price targets are: 0.06 > 0.06 > 0.06.

Tweet this
Enzon Pharmaceuticals Inc Daily Support & Resistance Chart

2. Trend Indicators

2.1 Moving Averages

Shows the moving average of the selected period.

  • Moving averages are lagging trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of Enzon Pharmaceuticals Inc. The current mas is .

The long score for the Moving Averages is 2/14.
The longshort score for the Moving Averages is -10/(-14 +14).

  • MA 20 trending up: The MA 20 is trending up. +1
  • Close > MA 20: The price is above the MA 20. +1
  • MA 20 < MA 50: The MA 20 is lower than the MA 50. -1
  • MA 20 < MA 100: The MA 20 is lower than the MA 100. -1
  • MA 20 < MA 200: The MA 20 is lower than the MA 200. -1
  • MA 50 trending down: The MA 50 is trending down. -1
  • Close < MA 50: The price is below the MA 50. -1
  • MA 50 < MA 100: The MA 50 is lower than the MA 100. -1
  • MA 50 < MA 200: The MA 50 is lower than the MA 200. -1
  • MA 100 trending down: The MA 100 is trending down. -1
  • Close < MA 100: The price is below the MA 100. -1
  • MA 100 < MA 200: The MA 100 is lower than the MA 200. -1
  • MA 200 trending down: The MA 200 is trending down. -1
  • Close < MA 200: The price is below the MA 200. -1

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200
MA 2020
MA 5050-
MA 100100--
MA 200200---

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

Enzon Pharmaceuticals Inc Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows the momentum of the selected period based on two moving averages.

  • MACD is a lagging momentum indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of Enzon Pharmaceuticals Inc. The current macd is -0.00184857.

The long score for the Moving Average Convergence/Divergence (MACD) is 1/4.
The longshort score for the Moving Average Convergence/Divergence (MACD) is -2/(-4 +4).

  • MACD line < signal line: The MACD line is below the signal line, which indicates a bearish signal in the market. This means that the negative momentum is currently stronger than the average momentum, suggesting that sellers are more active than buyers, and there's a higher probability of the Enzon price going down in the near term. -2
  • MACD < 0: The MACD is below the zero line (centerline), it indicates a bearish signal for Enzon. This means that the short-term moving average is lower than the long-term moving average, signaling negative momentum and suggesting a higher likelihood of the Enzon price continuing to fall in the near future. It indicates that sellers are gaining control, and there is negativism in the market, leading to potential price decreases. -1
  • Trending up: The MACD line is trending up. This indicates that the short-term moving average is rising faster than the long-term moving average, suggesting positive momentum in the market. This signals that buyers are becoming more active and confident, leading to potential price increases as traders anticipate further gains and are willing to buy at higher prices. +1
Enzon Pharmaceuticals Inc Daily Moving Average Convergence/Divergence (MACD) ChartEnzon Pharmaceuticals Inc Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of Enzon Pharmaceuticals Inc. The current adx is 12.62.

The long score for the Directional Movement Index (DMI) is 2/7.
The longshort score for the Directional Movement Index (DMI) is 2/(-7 +7).

  • PLUS_ID > MINUS_DI: The +DI line is above the -DI line. This indicates a bullish signal in the market, as the positive directional movement is currently stronger than the negative directional movement, showing that buyers have the upper hand. Market psychology suggests that traders are optimistic, expecting further price increases, and are more willing to buy Enzon shares, leading to potential upward momentum in its price. +1
  • PLUS_ID > MINUS_DI && ADX < 25 && ADX trending up: The ADX is below 25 and indicates a weak or no trend. However, the ADX is rising and a new bullish trend could be forming. +1
Enzon Pharmaceuticals Inc Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • Shows the current trend.
  • Shows potential entry signals.
  • Shows  potential exit signals.
  • Can be used to place trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of Enzon Pharmaceuticals Inc. The current sar is 0.0954337.

The long score for the Parabolic SAR is 0/1.
The longshort score for the Parabolic SAR is -1/(-1 +1).

  • Close < SAR: The price is below the SAR. It's generally considered a bearish signal. -1
Enzon Pharmaceuticals Inc Daily Parabolic SAR Chart

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentum indicator, meaning the signals are instant.
  • Ranges between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of Enzon Pharmaceuticals Inc. The current rsi is 51.06. The current phase is Correction in bear market.

The long score for the Relative Strength Index (RSI) is 4/13.
The longshort score for the Relative Strength Index (RSI) is 4/(-13 +13).

  • Correction in bear market: Extended price decline in a downtrend, significant pullback. Consider reducing exposure, wait for signs of trend reversal.
  • Trending up: The RSI is trending up. +1
Enzon Pharmaceuticals Inc Daily Relative Strength Index (RSI) ChartEnzon Pharmaceuticals Inc Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

Compares a certain price to multiple prices ranging over time.

  • Leading momentum indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • Ranges between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of Enzon Pharmaceuticals Inc. The current phase is Continuation in bear market.

The long score for the Stochastic Oscillator is 3/6.
The longshort score for the Stochastic Oscillator is 2/(-6 +6).

  • STOCH < 50: The STOCH %K is below 50. There are more sellers than buyers. -1
  • STOCH %K line > STOCH %D line: The STOCH %K line is above the STOCH %D line, which indicates a bullish signal in the market. This means that the positive momentum is currently stronger than the average momentum, suggesting that buyers are more active than sellers, and there's a higher probability of the Enzon price going up in the near term. +2
  • Trending up: The STOCH %K is trending up. +1
Enzon Pharmaceuticals Inc Daily Stochastic Oscillator ChartEnzon Pharmaceuticals Inc Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero, the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of Enzon Pharmaceuticals Inc. The current cci is 12.78.

Enzon Pharmaceuticals Inc Daily Commodity Channel Index (CCI) ChartEnzon Pharmaceuticals Inc Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of Enzon Pharmaceuticals Inc. The current cmo is 6.48405447.

The long score for the Chande Momentum Oscillator (CMO) is 1/1.
The longshort score for the Chande Momentum Oscillator (CMO) is 1/(-1 +1).

  • CMO > 0: The CMO is above 0, the momentum of the price is positive, indicating a potential uptrend in the price. +1
Enzon Pharmaceuticals Inc Daily Chande Momentum Oscillator (CMO) ChartEnzon Pharmaceuticals Inc Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

 Shows the current price relative to the highest high over the last 14 days.
 

  • Lagging momentum indicator
  • Ranging between 0 and -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of Enzon Pharmaceuticals Inc. The current willr is -55.

The long score for the Williams %R is 0/1.
The longshort score for the Williams %R is 0/(-1 +1).

  • WILLR between -80 and -20: The Williams %R is between -80 and -20. This indicates that Enzon is trading in a neutral price range, neither oversold nor overbought, suggesting a balanced market condition without any extreme price signals.
Enzon Pharmaceuticals Inc Daily Williams %R ChartEnzon Pharmaceuticals Inc Daily Williams %R Chart

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversold 

Score

Let's take a look at the Bollinger Bands of Enzon Pharmaceuticals Inc.

Enzon Pharmaceuticals Inc Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of Enzon Pharmaceuticals Inc. The current atr is 0.00946025.

Enzon Pharmaceuticals Inc Daily Average True Range (ATR) ChartEnzon Pharmaceuticals Inc Daily Average True Range (ATR) Chart

5. Volume Indicators

5.1 On-Balance Volume (OBV)

 Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of Enzon Pharmaceuticals Inc. The current obv is -558,675.

Enzon Pharmaceuticals Inc Daily On-Balance Volume (OBV) ChartEnzon Pharmaceuticals Inc Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of Enzon Pharmaceuticals Inc. The current mfi is 39.72.

The long score for the Money Flow Index (MFI) is 0/2.
The longshort score for the Money Flow Index (MFI) is -1/(-2 +2).

  • MFI < 50: -1
Enzon Pharmaceuticals Inc Daily Money Flow Index (MFI) ChartEnzon Pharmaceuticals Inc Daily Money Flow Index (MFI) Chart

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for Enzon Pharmaceuticals Inc.

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2023-12-01STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-05DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
2023-12-11STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-12MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
2023-12-14CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2023-12-15STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2023-12-18WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2023-12-20MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2023-12-26DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2023-12-29MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2024-01-02MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-01-03STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-01-04CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-01-05CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-01-08SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2024-01-10STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-12CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-01-16CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-01-18CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-01-19STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-01-23STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-24MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-01-25STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-30MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
2024-01-31CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-02-02SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-02-05STOCH LONG EXITThe %K line crosses below the %D line.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-02-08CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-02-09DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2024-02-12MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-02-13STOCH SHORT EXITThe %K line crosses above the %D line.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-02-14DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-02-15STOCH SHORT EXITThe %K line crosses above the %D line.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-02-20STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-02-21MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-02-22DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2024-02-26MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
2024-02-27MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-02-28WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-03-01STOCH SHORT EXITThe %K line crosses above the %D line.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-03-04ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-03-05ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-03-07MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-08MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2024-03-11CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-03-12MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-03-13STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2024-03-19MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-03-20ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-03-21MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-03-22MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-03-26MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-03-27DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-04-01DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
STOCH LONG EXITThe %K line crosses below the %D line.
2024-04-02CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-04-03MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
2024-04-05STOCH LONG EXITThe %K line crosses below the %D line.
2024-04-08MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-04-09CCI LONG ENTRY SHORT CLOSE100 crossover to upside
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-04-11STOCH LONG EXITThe %K line crosses below the %D line.
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2024-04-15DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-04-16MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-04-17DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
2024-04-19STOCH LONG EXITThe %K line crosses below the %D line.
2024-04-23CMO LONG ENTRY SHORT CLOSEZero line crossover to upside

6.3. Candlestick Patterns

Enzon Pharmaceuticals Inc Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of Enzon Pharmaceuticals Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5051.064
Ma 20Greater thanMa 500.077
Ma 50Greater thanMa 1000.078
Ma 100Greater thanMa 2000.088
OpenGreater thanClose0.078
Total1/5 (20.0%)
Penke

Good job! You gained 25 XP and 0   0   10 . What's next:

  • Share my analysis of Enzon with someone you think should read this too:
  • Are you bullish or bearish on Enzon? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about Enzon? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about Enzon Pharmaceuticals Inc

I send you an email if I find something interesting about Enzon Pharmaceuticals Inc.


Comments

How you think about this?

Leave a comment

Stay informed about Enzon Pharmaceuticals Inc.

Receive notifications about Enzon Pharmaceuticals Inc in your mailbox!